Six inmates were charged in a Feb. 22 melee that left five inmates hospitalized, including Karl Jordan Jr., one of the two men convicted last year in the 2002 slaying of Jam Master Jay ...

Former Blue Jays reliever Jay Jackson is taking his talents to Mexico. The right-hander has signed a one-year deal with Bravos de León, as reported on their social media account last week. Jays ...

Jay-Z is suing an anonymous woman who'd accused him of sexually assaulting her in 2000 in a December lawsuit before voluntarily dismissing the case two months later. Though Jay-Z's legal team ...

As the Cambridge drugmaker contemplates its future, the biotech’s chief medical officer has become the latest executive to exit the company. As Sage Therapeutics Inc. contemplates its path ...

Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage ...

The Brooklyn rapper accuses her and her attorneys of trying to extort him by filing the lawsuit that was recently withdrawn Brooklyn billionaire Shawn “Jay-Z” Carter is suing the woman ...

Jay-Z is suing his former rape accuser, claiming she has admitted her story was false. Weeks after the woman identified only as Jane Doe dropped her allegations, the musician is suing her and her ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 9 unusual trades. Delving into the details ...

Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) has been given a consensus recommendation of “Hold” by the nineteen ratings firms that are currently covering the stock, MarketBeat ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a rare blood cancer — achieving the efficacy goals of a Phase 3 study.

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana ...